Good morning, and welcome to Vimian's third quarter earnings call for 2026. Q3 third quarter earnings call. 2026. I'm Ali Tajbakhsh, Group CEO, and I will, together with our CFO, present our results for the third quarter. We continue to deliver strong performance with robust revenue and earnings growth in the quarter. Organic growth remains at double digits, which is well ahead of the overall animal health market. Our cash flow improved significantly compared to the previous quarter with operational cash conversion of 71%. We also see our M&A pipeline progressing in the right direction. And after the end of the quarter, we entered soft tissue surgery through the acquisition of Norfolk Medical Products in the US. On the management side, we finalized the recruitment of our new Head of Specialty Pharma, Hans Kahlert, bringing on board another highly experienced leader to the team, and promoted long-term team member Andrea Tidholm as Head of M&A.
Our business continues to outperform the overall animal health market, which reflects the strength of our strategy with a focus on attractive market niches, as well as a strong brand portfolio and disciplined execution. Looking at the numbers more specifically, we report 15% revenue growth and reached €120.3 million in revenues in the third quarter. Organic growth was 11% with strong momentum across all segments, 3% contribution from acquisitions, and 1% positive impact from currency movements. Adjusted EBITDA grew 14% to €29.2 million, with strong growth across all four segments. The adjusted EBITDA margin was 24.3%. Moving on to Specialty Pharma, the segment's underlying business momentum remains strong, with 7% organic growth, driven by double-digit growth in the therapeutic areas. Allergy, dermatology, and specialty pharmaceuticals. As previously communicated, the therapeutic area of specialized nutrition was impacted in the third quarter by a strong prior-year comparison. Adjusting for the impact from the sales campaign in specialized nutrition, organic growth in Specialty Pharma was 11% in the third quarter. During the quarter, we launched an updated version of our allergy test platform, Pet Allergy Explorer, or PAX, that covers an additional 25 allergens. PAX is the most advanced veterinary allergy test, and there are several third-party scientific studies reaffirming the test platform's ability to outperform other tests on the market. We continue to drive strong profitability in Specialty Pharma, and adjusted EBITDA grew 12% to €15.2 million, and adjusted EBITDA margin improved to 30.3%. Our MedTech business achieved another quarter of double-digit growth, reaching 15% in Q3. Both the dental and orthopedic businesses delivered double-digit growth in the third quarter. In the dental business, growth was driven by strong commercial execution and deepened penetration of key customer accounts in the US, as well as strong growth in APAC. In the. In the orthopedic business, growth was led by APAC and Europe, and our North American business delivered another quarter of growth in unchanged market conditions. We continued to drive education in the quarter and trained 1,300 veterinarians across our dental and orthopedic businesses. Adjusted EBITDA grew 20% to €10.5 million, and adjusted EBITDA margin improved to 24.4%, driven by strong growth and improved gross margin in our dental business. I am pleased with the development; our business and the new management team continue to review the business to address operational improvements. In our veterinary services business, the momentum remains strong, with 10% organic growth and 12,400 member clinics at the end of the quarter. During the quarter, we officially entered two new countries, which we talked about previously, Japan and Portugal, receiving positive feedback from the veterinary community. Adjusted EBITDA grew 28% to €5.9 million, and adjusted EBITDA margin improved to 30.5%, including positive effects in the quarter from mix and our strategic partner agreements. Our diagnostic business delivered 13% organic growth in the quarter, driven by extraction and PCR test sales in the livestock business. Adjusted EBITDA grew to €0.5 million. The adjusted EBITDA margin was 7.2%, including our investment to diversify companion animal diagnostics. Looking at our M&A activities, we have completed five acquisitions year-to-date and continue to have an active pipeline covering both large new platform acquisitions as well as smaller bolt-ons. Earlier this week, we signed the acquisition of Norfolk Medical Products, a leading niche provider in soft tissue surgery. Norfolk is a US-based business that develops, manufactures, and sells specialized implants and consumables, including, for example, a well-renowned urinary bypass implant for cats and dogs. The acquisition adds annual revenues of around $6.9 million and expands our MedTech offering into a new, fast-growing niche. Norfolk's portfolio is complementary to our existing surgical offering and operating model and is well-aligned with our focus on close relationships with the specialist community and education to unlock market growth. The profile of the customer base is also largely the same as ours. Many orthopedic clinics also do soft tissue surgery, and Norfolk Medical Products has currently a very small sales force, so we see good opportunities to grow the business by leveraging our MedTech sales force across the globe. We continue to deliver on our sustainability agenda, focusing on animals, people, and the planet, integrated into the core of our operations. In the quarter, we completed our employee experience survey with continued high engagement scores. We delivered. We also held our first Global Leader conference with 100 leaders from around the world to strengthen the cross-company culture and collaboration across the group. And with that, I will hand over to Juan for deeper insights into the financials. Thank you very much and good morning, everyone. As mentioned, I will give you a more detailed view on the financial development in the third quarter. Adjusted EBITDA in the third quarter was €29.2 million, an increase of 14%, corresponding to an adjusted EBITDA margin of 24.3%. As we have previously stated, we foresee a more stable margin development for the full year 2026 versus 2025, driven by our investments to drive growth in the MedTech segment. The slightly lower margin in the third quarter, specifically compared to the same period last year, is primarily a result of higher central costs. Central costs amounted to €3.0 million in the quarter, an increase from €1.8 million last year. The increase is mainly a result of expenses related to our long-term incentive programs. In total, €0.6 million in the quarter. These are non-IFRS, non-cash expenses that will recur for the duration of the three-year programs. We report an operating profit of €20.5 million, a 17% increase from last year's result of €17.5 million. Items affecting comparability were similar to the same period last year and totaled -€2.1 million, mainly attributed to acquisition costs in MedTech and veterinary services. Net financial items amounted to -€6.9 million and consisted of three main parts: first, financing expenses of -€4.2 million, with an average interest rate of 4.0% during the quarter, partly offset by interest income of €0.8 million; second, a quarterly discounting impact of -€0.9 million; and third, a negative impact of -€2.2 million from probability adjustments related to contingent considerations, mainly from new acquisitions. And lastly, a negative impact of 0.5 million from exchange rate effects on the revaluation of debt. Income tax expense for the quarter was €4.3 million, at an effective tax rate of 31% in the quarter. The tax expense as a percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses. In total, this resulted in a profit for the period of €9.3 million, with an earnings per share of €0.02 for the quarter.
Cash flow from operating activities reached €22.6 million, corresponding to a cash conversion defined as operating cash flow in relation to EBITA of 71% for the third quarter. Net working capital amounted to €116.4 million at the end of the quarter, equal to 25% of revenue and an increase from 114.1 million at the end of the second quarter, which equaled 26% of revenue. Cash flow from investing activities amounted to -21.0 million, primarily consisting of acquisition and earn-out payments. Capital expenditure amounted to 4.1 million, which is 3% of total revenue, with 2.9 million related to investments in internal R&D and software development, and investments in property, plant and equipment amounted to 1.2 million. Cash flow from financing activities totaled €2.4 million, mainly from proceeds from borrowings. At the end of the quarter, net debt amounted to 262.4 million, which is down from 273.7 million at the end of the second quarter. Cash and cash equivalents amounted to 55.6 million, an increase compared to 51.6 million at the end of June. External lending was 263.1 million at the end of the third quarter. This resulted in a leverage at the end of the quarter equal to 2.0x, a decrease from 2.1x at the end of the second quarter. We continue to be well capitalized with an ability to execute on our strengthened acquisition pipeline. With this financial review, I hand the word back to Ali for concluding remarks.
Thank you very much, Karl-Johan.